bryostatin 16: from Bugula neritina; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Flora | Rank | Flora Definition | Family | Family Definition |
---|---|---|---|---|
Bugula | genus | [no description available] | Lamiaceae | The mint plant family. They are characteristically aromatic, and many of them are cultivated for their oils. Most have square stems, opposite leaves, and two-lipped, open-mouthed, tubular corollas (united petals), with five-lobed, bell-like calyxes (united sepals).[MeSH] |
ID Source | ID |
---|---|
PubMed CID | 10581141 |
CHEMBL ID | 509516 |
MeSH ID | M0268760 |
Synonym |
---|
CHEMBL509516 , |
bryostatin 16 |
bdbm50292351 |
[(1s,3s,5z,7r,8e,13e,15s,17r,21r,23r,25s)-1,21-dihydroxy-17-[(1r)-1-hydroxyethyl]-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.13,7.111,15]nonacosa-8,11-dien-25-yl] 2,2-dimethylpropanoate |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Protein kinase C alpha type | Homo sapiens (human) | Ki | 0.1180 | 0.0002 | 1.0945 | 6.9600 | AID400689 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
ciliary basal body | Protein kinase C alpha type | Homo sapiens (human) |
nucleoplasm | Protein kinase C alpha type | Homo sapiens (human) |
cytoplasm | Protein kinase C alpha type | Homo sapiens (human) |
mitochondrion | Protein kinase C alpha type | Homo sapiens (human) |
endoplasmic reticulum | Protein kinase C alpha type | Homo sapiens (human) |
cytosol | Protein kinase C alpha type | Homo sapiens (human) |
plasma membrane | Protein kinase C alpha type | Homo sapiens (human) |
mitochondrial membrane | Protein kinase C alpha type | Homo sapiens (human) |
perinuclear region of cytoplasm | Protein kinase C alpha type | Homo sapiens (human) |
extracellular exosome | Protein kinase C alpha type | Homo sapiens (human) |
alphav-beta3 integrin-PKCalpha complex | Protein kinase C alpha type | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID400690 | Cytotoxicity against mouse P388 cells | 1996 | Journal of natural products, Mar, Volume: 59, Issue:3 | Antineoplastic agents. 340. Isolation and structural elucidation of bryostatins 16-18. |
AID400689 | Displacement of [3H]PDBu form PKCalpha | 1996 | Journal of natural products, Mar, Volume: 59, Issue:3 | Antineoplastic agents. 340. Isolation and structural elucidation of bryostatins 16-18. |
AID400693 | Growth inhibition of human A498 cells by NCI-method | 1996 | Journal of natural products, Mar, Volume: 59, Issue:3 | Antineoplastic agents. 340. Isolation and structural elucidation of bryostatins 16-18. |
AID400696 | Growth inhibition of human SK-MEL-5 cells by NCI-method | 1996 | Journal of natural products, Mar, Volume: 59, Issue:3 | Antineoplastic agents. 340. Isolation and structural elucidation of bryostatins 16-18. |
AID400691 | Growth inhibition of human OVCAR-3 cells by NCI-method | 1996 | Journal of natural products, Mar, Volume: 59, Issue:3 | Antineoplastic agents. 340. Isolation and structural elucidation of bryostatins 16-18. |
AID400692 | Growth inhibition of human SF295 cells by NCI-method | 1996 | Journal of natural products, Mar, Volume: 59, Issue:3 | Antineoplastic agents. 340. Isolation and structural elucidation of bryostatins 16-18. |
AID400694 | Growth inhibition of human NCI-H460 cells by NCI-method | 1996 | Journal of natural products, Mar, Volume: 59, Issue:3 | Antineoplastic agents. 340. Isolation and structural elucidation of bryostatins 16-18. |
AID400695 | Growth inhibition of human KM20L2 cells by NCI-method | 1996 | Journal of natural products, Mar, Volume: 59, Issue:3 | Antineoplastic agents. 340. Isolation and structural elucidation of bryostatins 16-18. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (20.00) | 18.2507 |
2000's | 3 (60.00) | 29.6817 |
2010's | 1 (20.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (18.21) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |